source
- Argenx acquires Unnatural Products for up to $1.15 billion to boost oral peptide platformArgenx announced it will buy biotech Unnatural Products, paying $550 million upfront with the total deal value potentially reaching $1.15 billion through development and regulatory milestones. The…
- Merck's efinopegdutide shows strong MASH resolution in phase 2b trialMerck & Co. reported results from a phase 2b trial (MK-6024-013) evaluating efinopegdutide, a GLP-1 and glucagon receptor co-agonist, in patients with metabolic dysfunction-associated steatohepatit…